Inhibitors of p21-activated kinases (PAKs)

Journal of Medicinal Chemistry

Volumn 58, Issue 1, 2015, Pages 111-129

  Rudolph, Joachim ^a   Crawford, James J ^a   Hoeflich, Klaus P ^b   Wang, Weiru ^a  

^a GENENTECH INC   (United States)

^b Blueprint Medicines   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BIARYL KETONE AZAINDOLE DERIVATIVE; DIBENZODIAZEPINE DERIVATIVE; MALEIMIDE; OXINDOLE; P21 ACTIVATED KINASE 1; P21 ACTIVATED KINASE 2; P21 ACTIVATED KINASE 3; P21 ACTIVATED KINASE 4; P21 ACTIVATED KINASE 5; P21 ACTIVATED KINASE 6; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDO[2,3 D ]PYRIMIDINE 7 ONE DERIVATIVE; UNCLASSIFIED DRUG; ISOENZYME; ISOPROTEIN; P21 ACTIVATED KINASE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST CARCINOMA; CANCER INHIBITION; CARCINOGENESIS; CELL ACTIVITY; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL TRANSFORMATION; COGNITIVE DEFECT; CONFORMATIONAL TRANSITION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG SOLUBILITY; GENETIC CODE; HUMAN; HYDROGEN BOND; NON SMALL CELL LUNG CANCER; NONHUMAN; NONSENSE MUTATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; VOLUME OF DISTRIBUTION; X LINKED MENTAL RETARDATION; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

CELL PROLIFERATION; CELL SURVIVAL; HUMANS; ISOENZYMES; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS; P21-ACTIVATED KINASES; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION;

EID: 84928427103     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501613q     Document Type: Article

References (97)

1. Radu, M.; Semenova, G.; Kosoff, R.; Chernoff, J. PAK signalling during the development and progression of cancer Nat. Rev. Cancer 2014, 14 (1) 13-25
2. Rudolph, J.; Crawford, J. J.; Hoeflich, K. P.; Chernoff, J. p21-activated kinase inhibitors Enzymes 2013, 34 (Part B) 157-180
3. Zhao, Z. S.; Manser, E. PAK family kinases: physiological roles and regulation Cell. Logistics 2012, 2 (2) 59-68
4. Ye, D. Z.; Field, J. PAK signaling in cancer Cell. Logistics 2012, 2 (2) 105-116
5. Allen, J. D.; Jaffer, Z. M.; Park, S. J.; Burgin, S.; Hofmann, C.; Sells, M. A.; Chen, S.; Derr-Yellin, E.; Michels, E. G.; McDaniel, A.; Bessler, W. K.; Ingram, D. A.; Atkinson, S. J.; Travers, J. B.; Chernoff, J.; Clapp, D. W. p21-activated kinase regulates mast cell degranulation via effects on calcium mobilization and cytoskeletal dynamics Blood 2009, 113 (12) 2695-2705
6. Chiang, Y. T.; Jin, T. p21-Activated protein kinases and their emerging roles in glucose homeostasis Am. J. Physiol.: Endocrinol. Metab. 2014, 306 (7) E707-E722
7. Ke, Y.; Lei, M.; Wang, X.; Solaro, R. J. Novel roles of PAK1 in the heart Cell. Logistics 2012, 2 (2) 89-94
8. Arias-Romero, L. E.; Chernoff, J. A tale of two Paks J. Biol. Cell 2008, 100, 97-108
9. Ottilie, S.; Miller, P. J.; Johnson, D. I.; Creasy, C. L.; Sells, M. A.; Bagrodia, S.; Forsburg, S. L.; Chernoff, J. Fission yeast pak1+ encodes a protein kinase that interacts with Cdc42p and is involved in the control of cell polarity and mating EMBO J. 1995, 14 (23) 5908-59019
10. Kelly, M. L.; Chernoff, J. Mouse models of PAK function Cell. Logistics 2012, 2 (2) 84-88
11. Meng, J.; Meng, Y.; Hanna, A.; Janus, C.; Jia, Z. Abnormal long-lasting synaptic plasticity and cognition in mice lacking the mental retardation gene Pak3 J. Neurosci. 2005, 25 (28) 6641-6650
12. Huang, W.; Zhou, Z.; Asrar, S.; Henkelman, M.; Xie, W.; Jia, Z. p21-Activated kinases 1 and 3 control brain size through coordinating neuronal complexity and synaptic properties Mol. Cell. Biol. 2011, 31 (3) 388-403
13. Tian, Y.; Lei, L.; Cammarano, M.; Nekrasova, T.; Minden, A. Essential role for the Pak4 protein kinase in extraembryonic tissue development and vessel formation Mech. Dev. 2009, 126 (8-9) 710-720
14. Tian, Y.; Lei, L.; Minden, A. A key role for Pak4 in proliferation and differentiation of neural progenitor cells Dev. Biol. 2011, 353 (2) 206-216
15. Nekrasova, T.; Jobes, M. L.; Ting, J. H.; Wagner, G. C.; Minden, A. Targeted disruption of the Pak5 and Pak6 genes in mice leads to deficits in learning and locomotion Dev. Biol. 2008, 322 (1) 95-108
16. Minden, A. PAK4-6 in cancer and neuronal development Cell. Logistics 2012, 2 (2) 95-104
17. GeneCards. http://www.genecards.org (accessed October, 1, 2014).
18. Ong, C. C.; Jubb, A. M.; Zhou, W.; Haverty, P. M.; Harris, A. L.; Belvin, M.; Friedman, L. S.; Koeppen, H.; Hoeflich, K. P. p21-activated kinase 1: PAK'ed with potential Oncotarget 2011, 2 (6) 491-496
19. Ong, C. C.; Jubb, A. M.; Haverty, P. M.; Zhou, W.; Tran, V.; Truong, T.; Turley, H.; O'Brien, T.; Vucic, D.; Harris, A. L.; Belvin, M.; Friedman, L. S.; Blackwood, E. M.; Koeppen, H.; Hoeflich, K. P. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (17) 7177-7182
20. Shrestha, Y.; Schafer, E. J.; Boehm, J. S.; Thomas, S. R.; He, F.; Du, J.; Wang, S.; Barretina, J.; Weir, B. A.; Zhao, J. J.; Polyak, K.; Golub, T. R.; Beroukhim, R.; Hahn, W. C. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling Oncogene 2012, 31 (29) 3397-3408
21. Curtis, C.; Shah, S. P.; Chin, S. F.; Turashvili, G.; Rueda, O. M.; Dunning, M. J.; Speed, D.; Lynch, A. G.; Samarajiwa, S.; Yuan, Y.; Gräf, S.; Ha, G.; Haffari, G.; Bashashati, A.; Russell, R.; McKinney, S.; Langerød, A.; Green, A.; Provenzano, E.; Wishart, G.; Pinder, S.; Watson, P.; Markowetz, F.; Murphy, L.; Ellis, I.; Purushotham, A.; Børresen-Dale, A. L.; Brenton, J. D.; Tavaré, S.; Caldas, C.; Aparicio, S.; Group, M. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups Nature 2012, 486 (7403) 346-352
22. Reddy, S. D.; Ohshiro, K.; Rayala, S. K.; Kumar, R. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions Cancer Res. 2008, 68 (20) 8195-200
23. Holm, C.; Rayala, S.; Jirström, K.; Stål, O.; Kumar, R.; Landberg, G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients J. Natl. Cancer Inst. 2006, 98 (10) 671-680
24. Wang, R. A.; Zhang, H.; Balasenthil, S.; Medina, D.; Kumar, R. PAK1 hyperactivation is sufficient for mammary gland tumor formation Oncogene 2006, 25 (20) 2931-2936
25. Arias-Romero, L. E.; Villamar-Cruz, O.; Huang, M.; Hoeflich, K. P.; Chernoff, J. PAK1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells Cancer Res. 2013, 73, 3671-3682
26. Ong, C. C.; Jubb, A. M.; Jakubiak, D.; Zhou, W.; Rudolph, J.; Haverty, P. M.; Kowanetz, M.; Yan, Y.; Tremayne, J.; Lisle, R.; Harris, A. L.; Friedman, L. S.; Belvin, M.; Middleton, M. R.; Blackwood, E. M.; Koeppen, H.; Hoeflich, K. P. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma J. Natl. Cancer Inst. 2013, 105 (9) 606-607
27. Chen, S.; Auletta, T.; Dovirak, O.; Hutter, C.; Kuntz, K.; El-ftesi, S.; Kendall, J.; Han, H.; Von Hoff, D. D.; Ashfaq, R.; Maitra, A.; Iacobuzio-Donahue, C. A.; Hruban, R. H.; Lucito, R. Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification Cancer Biol. Ther. 2008, 7 (11) 1793-1802
28. Kimmelman, A. C.; Hezel, A. F.; Aguirre, A. J.; Zheng, H.; Paik, J. H.; Ying, H.; Chu, G. C.; Zhang, J. X.; Sahin, E.; Yeo, G.; Ponugoti, A.; Nabioullin, R.; Deroo, S.; Yang, S.; Wang, X.; McGrath, J. P.; Protopopova, M.; Ivanova, E.; Zhang, J.; Feng, B.; Tsao, M. S.; Redston, M.; Protopopov, A.; Xiao, Y.; Futreal, P. A.; Hahn, W. C.; Klimstra, D. S.; Chin, L.; DePinho, R. A. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (49) 19372-19377
29. Fawdar, S.; Trotter, E. W.; Li, Y.; Stephenson, N. L.; Hanke, F.; Marusiak, A. A.; Edwards, Z. C.; Ientile, S.; Waszkowycz, B.; Miller, C. J.; Brognard, J. Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer Proc. Natl. Acad. Sci. U.S.A. 2013, 110 (30) 12426-12431
30. Linch, M.; Sanz-Garcia, M.; Soriano, E.; Zhang, Y.; Riou, P.; Rosse, C.; Cameron, A.; Knowles, P.; Purkiss, A.; Kjaer, S.; McDonald, N. Q.; Parker, P. J. A cancer-associated mutation in atypical protein kinase C occurs in a substrate-specific recruitment motif Sci. Signal 2013, 6 (293) ra82
31. Data from COSMIC database: http://cancer.sanger.ac.uk (accessed August, 2, 2014).
32. Qiu, R. G.; Chen, J.; Kirn, D.; McCormick, F.; Symons, M. An essential role for Rac in Ras transformation Nature 1995, 374 (6521) 457-459
33. Stengel, K. R.; Zheng, Y. Essential role of Cdc42 in Ras-induced transformation revealed by gene targeting PLoS One 2012, 7 (6) e37317
34. Chow, H. Y.; Jubb, A. M.; Koch, J. N.; Jaffer, Z. M.; Stepanova, D.; Campbell, D. A.; Duron, S. G.; O'Farrell, M.; Cai, K. Q.; Klein-Szanto, A. J.; Gutkind, J. S.; Hoeflich, K. P.; Chernoff, J. p21-activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model Cancer Res. 2012, 72 (22) 5966-5975
35. Balbin, O. A.; Prensner, J. R.; Sahu, A.; Yocum, A.; Shankar, S.; Malik, R.; Fermin, D.; Dhanasekaran, S. M.; Chandler, B.; Thomas, D.; Beer, D. G.; Cao, X.; Nesvizhskii, A. I.; Chinnaiyan, A. M. Reconstructing targetable pathways in lung cancer by integrating diverse omics data Nat. Commun. 2013, 4, 2617
36. Liu, Y.; Xiao, H.; Tian, Y.; Nekrasova, T.; Hao, X.; Lee, H. J.; Suh, N.; Yang, C. S.; Minden, A. The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice Mol. Cancer Res. 2008, 6 (7) 1215-1224
37. Gnad, F.; Young, A.; Zhou, W.; Lyle, K.; Ong, C. C.; Stokes, M. P.; Silva, J. C.; Belvin, M.; Friedman, L. S.; Koeppen, H.; Minden, A.; Hoeflich, K. Systems-wide analysis of K-Ras, Cdc42 and PAK4 signaling by quantitative phosphoproteomics Mol. Cell. Proteomics 2013, 12 (8) 2070-2080
38. Ma, Q. L.; Yang, F.; Frautschy, S. A.; Cole, G. M. PAK in Alzheimer disease, Huntington disease and X-linked mental retardation Cell. Logistics 2012, 2 (2) 117-125
39. Ma, Q. L.; Yang, F.; Calon, F.; Ubeda, O. J.; Hansen, J. E.; Weisbart, R. H.; Beech, W.; Frautschy, S. A.; Cole, G. M. p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis J. Biol. Chem. 2008, 283 (20) 14132-14143
40. Nguyen, T. V.; Galvan, V.; Huang, W.; Banwait, S.; Tang, H.; Zhang, J.; Bredesen, D. E. Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664 J. Neurochem. 2008, 104 (4) 1065-1080
41. Allen, K. M.; Gleeson, J. G.; Bagrodia, S.; Partington, M. W.; MacMillan, J. C.; Cerione, R. A.; Mulley, J. C.; Walsh, C. A. PAK3 mutation in nonsyndromic X-linked mental retardation Nat. Genet. 1998, 20 (1) 25-30
42. Chen, L. Y.; Rex, C. S.; Babayan, A. H.; Kramár, E. A.; Lynch, G.; Gall, C. M.; Lauterborn, J. C. Physiological activation of synaptic Rac>PAK (p-21 activated kinase) signaling is defective in a mouse model of fragile X syndrome J. Neurosci. 2010, 30 (33) 10977-10984
43. Say, E.; Tay, H. G.; Zhao, Z. S.; Baskaran, Y.; Li, R.; Lim, L.; Manser, E. A functional requirement for PAK1 binding to the KH(2) domain of the fragile X protein-related FXR1 Mol. Cell 2010, 38 (2) 236-249
44. Churin, Y.; Kardalinou, E.; Meyer, T. F.; Naumann, M. Pathogenicity island-dependent activation of Rho GTPases Rac1 and Cdc42 in Helicobacter pylori infection Mol. Microbiol. 2001, 40 (4) 815-823
45. Goehring, U. M.; Schmidt, G.; Pederson, K. J.; Aktories, K.; Barbieri, J. T. The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a GTPase-activating protein for Rho GTPases J. Biol. Chem. 1999, 274 (51) 36369-36372
46. Pielage, J. F.; Powell, K. R.; Kalman, D.; Engel, J. N. RNAi screen reveals an Abl kinase-dependent host cell pathway involved in Pseudomonas aeruginosa internalization PLoS Pathog. 2008, 4 (3) e1000031
47. Foster, J. L.; Garcia, J. V. HIV-1 Nef: at the crossroads Retrovirology 2008, 5, 84
48. Wolf, D.; Witte, V.; Laffert, B.; Blume, K.; Stromer, E.; Trapp, S.; d'Aloja, P.; Schürmann, A.; Baur, A. S. HIV-1 Nef associated PAK and PI3-kinases stimulate Akt-independent Bad-phosphorylation to induce anti-apoptotic signals Nat. Med. 2001, 7 (11) 1217-1224
49. Nguyen, D. G.; Wolff, K. C.; Yin, H.; Caldwell, J. S.; Kuhen, K. L. "UnPAKing" human immunodeficiency virus (HIV) replication: using small interfering RNA screening to identify novel cofactors and elucidate the role of group I PAKs in HIV infection J. Virol 2006, 80 (1) 130-137
50. Pascua, P. N.; Lee, J. H.; Song, M. S.; Park, S. J.; Baek, Y. H.; Ann, B. H.; Shin, E. Y.; Kim, E. G.; Choi, Y. K. Role of the p21-activated kinases (PAKs) in influenza A virus replication Biochem. Biophys. Res. Commun. 2011, 414 (3) 569-574
51. Jha, R. K.; Strauss, C. E. 3D structure analysis of PAKs: a clue to the rational design for affinity reagents and blockers Cell. Logistics 2012, 2 (2) 69-77
52. Lei, M.; Lu, W.; Meng, W.; Parrini, M. C.; Eck, M. J.; Mayer, B. J.; Harrison, S. C. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch Cell 2000, 102 (3) 387-397
53. Parrini, M. C.; Lei, M.; Harrison, S. C.; Mayer, B. J. Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rac1 Mol. Cell 2002, 9 (1) 73-83
54. Baskaran, Y.; Ng, Y. W.; Selamat, W.; Ling, F. T.; Manser, E. Group I and II mammalian PAKs have different modes of activation by Cdc42 EMBO Rep. 2012, 13, 653-659
55. Ha, B. H.; Davis, M. J.; Chen, C.; Lou, H. J.; Gao, J.; Zhang, R.; Krauthammer, M.; Halaban, R.; Schlessinger, J.; Turk, B. E.; Bloggon, T. J. Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate Proc. Natl. Acad. Sci. U.S.A. 2012, 109 (40) 16107-16112
56. Blanck, S.; Maksimoska, J.; Baumeister, J.; Harms, K.; Marmorstein, R.; Meggers, E. The art of filling protein pockets efficiently with octahedral metal complexes Angew. Chem., Int. Ed. 2012, 51 (21) 5244-5246
57. Eswaran, J.; Lee, W. H.; Debreczeni, J. E.; Filippakopoulos, P.; Turnbull, A.; Fedorov, O.; Deacon, S. W.; Peterson, J. R.; Knapp, S. Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs Structure 2007, 15 (2) 201-13
58. Rüegg, U. T.; Burgess, G. M. Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases Trends Pharmacol. Sci. 1989, 10 (6) 218-220
59. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26 (1) 127-132
60. Maksimoska, J.; Feng, L.; Harms, K.; Yi, C.; Kissil, J.; Marmorstein, R.; Meggers, E. Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes J. Am. Chem. Soc. 2008, 130 (47) 15764-15765
61. Tonani, R.; Bindi, S.; Fancelli, D.; Pittala, V.; Danello, M. Preparation of heterobicyclic pyrazole derivatives as kinase inhibitors. WO2004007504A1, July 11, 2003.
62. Guo, C.; Johnson, M. C.; Li, H.; Marakovits, J. T.; McAlpine, I. J.; Dong, L. Pyrimidine aminopyrazole compounds, potent kinase inhibitors. WO2007/023382A2, August 17, 2006.
63. Dong, L.; Guo, C.; Hong, Y.; Johnson, M. C.; Kephart, S. E.; Li, H.; McAlpine, I. J.; Tikhe, J. G.; Yang, A.; Zhang, J. Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. WO2007/072153A2, December 12, 2006.
64. Bouzida, D.; Dong, L.; Guo, C.; Hong, Y.; Li, H.; Marakovits, J. T.; Yang, A.; Zhang, J. Pyrrolopyrazoles, potent kinase inhibitors. WO2006/072831A1, December 28, 2005.
65. Guo, C.; McAlpine, I.; Zhang, J.; Knighton, D. D.; Kephart, S.; Johnson, M. C.; Li, H.; Bouzida, D.; Yang, A.; Dong, L.; Marakovits, J.; Tikhe, J.; Richardson, P.; Guo, L. C.; Kania, R.; Edwards, M. P.; Kraynov, E.; Christensen, J.; Piraino, J.; Lee, J.; Dagostino, E.; Del-Carmen, C.; Deng, Y. L.; Smeal, T.; Murray, B. W. Discovery of pyrroloaminopyrazoles as novel PAK inhibitors J. Med. Chem. 2012, 55 (10) 4728-4739
66. Murray, B. W.; Guo, C.; Piraino, J.; Westwick, J. K.; Zhang, C.; Lamerdin, J.; Dagostino, E.; Knighton, D.; Loi, C. M.; Zager, M.; Kraynov, E.; Popoff, I.; Christensen, J. G.; Martinez, R.; Kephart, S. E.; Marakovits, J.; Karlicek, S.; Bergqvist, S.; Smeal, T. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth Proc. Natl. Acad. Sci. U.S.A. 2010, 107 (20) 9446-9451
67. Rosen, L. S.; Blumenkopf, T. A.; Breazna, A.; Darang, S.; Gallo, J. D.; Goldman, J.; Wang, D.; Mileshkin, L.; Eckhardt, S. G. Phase 1, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of single-agent PF-03758309, an oral PAK inhibitor, in patients with advanced solid tumors. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, Nov 12-16, 2011; AACR: Philadelphia, PA, 2011
68. Mol. Cancer Ther. 2011, 10 (Suppl. 11), Abstract A177.
69. Guo, C.; Zhang, J.; McAlpine, I.; Johnson, C.; Marakovits, J.; Dong, L.; Kephart, S.; Yang, A.; Tikhe, J.; Li, H.; Guo, L.; Bouzida, D.; Deng, Y. L.; Knighton, D.; Piraino, J.; Lee, J.; Smeal, T.; Christensen, J.; Kraynov, E.; Loi, C. M.; Younis, H.; Dagostino, E.; Murray, B. W. Discovery of p21-activated kinase inhibitor PF-03758309 Mol. Targets Cancer Ther. 2009, 8 (12, Suppl.) PR-2
70. Genentech, unpublished results.
71. Callow, M. G.; Clairvoyant, F.; Zhu, S.; Schryver, B.; Whyte, D. B.; Bischoff, J. R.; Jallal, B.; Smeal, T. Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines J. Biol. Chem. 2002, 277 (1) 550-558
72. Tabusa, H.; Brooks, T.; Massey, A. J. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling Mol. Cancer Res. 2013, 11 (2) 109-121
73. Bebbington, D.; Binch, H.; Charrier, J. D.; Everitt, S.; Fraysse, D.; Golec, J.; Kay, D.; Knegtel, R.; Mak, C.; Mazzei, F.; Miller, A.; Mortimore, M.; O'Donnell, M.; Patel, S.; Pierard, F.; Pinder, J.; Pollard, J.; Ramaya, S.; Robinson, D.; Rutherford, A.; Studley, J.; Westcott, J. The discovery of the potent aurora inhibitor MK-0457 (VX-680) Bioorg. Med. Chem. Lett. 2009, 19 (13) 3586-3592
74. Ioannidis, S.; Lamb, M. L.; Wang, T.; Almeida, L.; Block, M. H.; Davies, A. M.; Peng, B.; Su, M.; Zhang, H. J.; Hoffmann, E.; Rivard, C.; Green, I.; Howard, T.; Pollard, H.; Read, J.; Alimzhanov, M.; Bebernitz, G.; Bell, K.; Ye, M.; Huszar, D.; Zinda, M. Discovery of 5-chloro- N 2-[(1 S)-1-(5-fluoropyrimidin-2-yl)ethyl]- N 4-(5-methyl-1 H -pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway J. Med. Chem. 2011, 54 (1) 262-276
75. Aliagas-Martin, I.; Crawford, J.; Lee, W.; Mathieu, S.; Rudolph, J. Serine/Threonine PAK1 Inhibitors. WO2013/026914A1, August 24, 2012.
76. Abdel-Magid, A. F. PAK1: A therapeutic target for cancer treatment ACS Med. Chem. Lett. 2013, 4 (5) 431-432
77. Abad-Zapatero, C.; Metz, J. T. Ligand efficiency indices as guideposts for drug discovery Drug Discov Today 2005, 10 (7) 464-469
78. Aliagas-Martin, I.; Crawford, J. J.; Mathieu, S.; Rudolph, J.; Lee, W. Preparation of pyridimidine-2,4-diamine derivatives as serine/threonine kinase inhibitors. WO2013092940A1, December 21, 2012.
79. Licciulli, S.; Maksimoska, J.; Zhou, C.; Troutman, S.; Kota, S.; Liu, Q.; Duron, S.; Campbell, D.; Chernoff, J.; Field, J.; Marmorstein, R.; Kissil, J. L. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas J. Biol. Chem. 2013, 288 (40) 29105-29114
80. Lu, H.; Schulze-Gahmen, U. Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition J. Med. Chem. 2006, 49 (13) 3826-3831
81. PDB code 2HY8: Lu, H.; Lei, M.; Schulze-Gahmen, U. Crystal structure of the complex between human Pak1-kinase and 3-hydroxystaurosporine. To be published.
82. Ong, C. C.; Gierke, S.; Pitt, C.; Cheng, C. K.; Zhou, W.; Jubb, A. M.; Strickland, L.; Schmidt, M.; Duron, S. G.; Campbell, D. A.; Zheng, W.; Dehdashti, S.; Shen, M.; Yang, N.; Behnke, M. L.; Huang, W.; McKew, J. C.; Chernoff, J.; Forrest, W.; Haverty, P. M.; Chin, S.-F.; Rakha, E. A.; Green, A. R.; Ellis, I. O.; Caldas, C.; O'Brien, T.; Friedman, L. S.; Koeppen, H.; Rudolph, J.; Hoeflich, K. P. Unpublished results.
83. Chow, H.-Y.; Dong, B.; Duron, S. G.; Campbell, D. A.; Ong, C. C.; Hoeflich, K. P.; Chang, L.-S.; Welling, D. B.; Yang, Z.-J.; Chernoff, J. Unpublished results.
84. Liao, J. J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors J. Med. Chem. 2007, 50 (3) 409-424
85. Goldstein, D. M.; Soth, M.; Gabriel, T.; Dewdney, N.; Kuglstatter, A.; Arzeno, H.; Chen, J.; Bingenheimer, W.; Dalrymple, S. A.; Dunn, J.; Farrell, R.; Frauchiger, S.; La Fargue, J.; Ghate, M.; Graves, B.; Hill, R. J.; Li, F.; Litman, R.; Loe, B.; McIntosh, J.; McWeeney, D.; Papp, E.; Park, J.; Reese, H. F.; Roberts, R. T.; Rotstein, D.; San Pablo, B.; Sarma, K.; Stahl, M.; Sung, M. L.; Suttman, R. T.; Sjogren, E. B.; Tan, Y.; Trejo, A.; Welch, M.; Weller, P.; Wong, B. R.; Zecic, H. Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8 H -pyrido[2,3- d ]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2 H -pyran-4-ylamino)pyrido[2,3- d ]pyrimidin-7(8 H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase J. Med. Chem. 2011, 54 (7) 2255-2265
86. Dolan, B. M.; Duron, S. G.; Campbell, D. A.; Vollrath, B.; Shankaranarayana Rao, B. S.; Ko, H. Y.; Lin, G. G.; Govindarajan, A.; Choi, S. Y.; Tonegawa, S. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486 Proc. Natl. Acad. Sci. U.S.A. 2013, 110 (14) 5671-5676
87. McCoull, W.; Hennessy, E. J.; Blades, K.; Box, M. R.; Chuaqui, C.; Dowling, J. E.; Davies, C. D.; Ferguson, A. D.; Goldberg, F. W.; Howe, N. J.; Kemmitt, P. D.; Lamont, G. M.; Madden, K.; McWhirter, C.; Varnes, J. G.; Ward, R. A.; Williams, J. D.; Yang, B. Identification and optimisation of 7-azaindole PAK1 inhibitors with improved potency and kinase selectivity MedChemComm 2014, 5, 1533-1539
88. Staben, S. T.; Feng, J. A.; Lyle, K.; Belvin, M.; Boggs, J.; Burch, J. D.; Chua, C. C.; Cui, H.; DiPasquale, A. G.; Friedman, L. S.; Heise, C.; Koeppen, H.; Kotey, A.; Mintzer, R.; Oh, A.; Roberts, D. A.; Rouge, L.; Rudolph, J.; Tam, C.; Wang, W.; Xiao, Y.; Young, A.; Zhang, Y.; Hoeflich, K. P. Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors J. Med. Chem. 2014, 57 (3) 1033-1045
89. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the "gatekeeper door": exploiting the active kinase conformation J. Med. Chem. 2010, 53 (7) 2681-94
90. Angiolini, M. Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis Future Med. Chem. 2011, 3 (3) 309-337
91. Wallin, J. J.; Guan, J.; Edgar, K. A.; Zhou, W.; Francis, R.; Torres, A. C.; Haverty, P. M.; Eastham-Anderson, J.; Arena, S.; Bardelli, A.; Griffin, S.; Goodall, J. E.; Grimshaw, K. M.; Hoeflich, K. P.; Torrance, C.; Belvin, M.; Friedman, L. S. Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes PLoS One 2012, 7 (5) e36402
92. Wong, L. E.; Chen, N.; Karantza, V.; Minden, A. The Pak4 protein kinase is required for oncogenic transformation of MDA-MB-231 breast cancer cells Oncogenesis 2013, 2, e50
93. Lindvall, M.; Karpov, A.; Bellamacina, C.; Daniel, D.; Fabbro, D.; Fernandez, C.; Jacob, S.; Jahnke, W.; Moebitz, H.; Pecchi, S.; Shoemaker, K.; Wang, J.; Breitenstein, W.; Gutmann, S.; Lagasse, S.; Machajewski, T.; Marzinzik, A.; Galuba, I.; Trappe, J.; Crawford, K.; Voliva, C.; Lai, A.; Hinh, L.; Rummel, G. Discovery of novel and highly selective allosteric inhibitors of PAK1. Abstracts of Papers, 246th National Meeting of the American Chemical Society, Indianapolis, IN, U.S., September 8-12, 2013; American Chemical Society: Washington, DC, 2013; MEDI-35.
94. Wenthur, C. J.; Lindsley, C. W. Classics in chemical neuroscience: clozapine ACS Chem. Neurosci. 2013, 4 (7) 1018-1025
95. Deacon, S. W.; Beeser, A.; Fukui, J. A.; Rennefahrt, U. E.; Myers, C.; Chernoff, J.; Peterson, J. R. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase Chem. Biol. 2008, 15 (4) 322-331
96. Viaud, J.; Peterson, J. R. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently Mol. Cancer Ther 2009, 8 (9) 2559-2565
97. Bamborough, P.; Brown, M. J.; Christopher, J. A.; Chung, C. W.; Mellor, G. W. Selectivity of kinase inhibitor fragments J. Med. Chem. 2011, 54 (14) 5131-5143